Related Experiment Videos

Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation

X Qian1, W C Dougall, M E Hellman

  • 1Department of Pathology and Laboratory Medicine, University of Pennsylvania, School of Medicine, Philadelphia 19104-6082.

Oncogene
|May 1, 1994
PubMed

Insights

Kinase-deficient Neu proteins suppress epidermal growth factor receptor (EGFR) function when heterodimerized, blocking EGFR-driven transformation and tumorigenicity. This dominant-negative effect highlights the role of receptor heterodimerization in oncogenesis.

Area of Science:

  • Cellular biology
  • Molecular oncology
  • Signal transduction

Background:

  • p185c-neu and epidermal growth factor receptor (EGFR) form active heterodimers upon overexpression, driving a transformed phenotype.
  • Kinase-deficient Neu proteins, when associated with EGFR, form defective or inactive heterodimeric complexes.

Purpose of the Study:

  • To investigate the biological impact of heterodimerization between EGFR and wild-type or kinase-deficient Neu proteins in living cells.
  • To elucidate the role of receptor heterodimerization in oncogenesis and signal transduction.

Main Methods:

  • Co-expression of EGFR with wild-type or kinase-deficient Neu proteins in cellular models.
  • Assessment of synergistic transformation, tumorigenicity, and EGFR ligand responses (e.g., EGF-dependent transformation, receptor endocytosis, DNA synthesis, EGF binding).

Main Results:

  • Co-expression of EGFR and kinase-deficient Neu proteins abolished synergistic transformation and tumorigenicity.
  • Normal EGFR responses to EGF were significantly suppressed, including loss of EGF-dependent transformation, reduced receptor endocytosis and turnover, diminished DNA synthesis, and decreased EGF binding affinity.
  • Kinase-deficient Neu proteins exhibit a dominant-negative mutant phenotype, suppressing normal EGFR function.

Conclusions:

  • Kinase-deficient Neu proteins suppress normal EGFR function, demonstrating a dominant-negative effect.
  • Receptor heterodimerization between EGFR and Neu/c-erbB2 plays a crucial role in interreceptor activation and synergistic signaling.
  • These interactions are implicated in the transition from normal receptor function to oncogenesis.

Related Concept Videos